NEW YORK, April 27, 2017 /PRNewswire/ --
Stock-Callers.com has initiated coverage on select Generic Drugs stocks, particularly: Mylan N.V. (NASDAQ: MYL), Allergan PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: HZNP), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). These companies operate in the Healthcare sector, which has been lackluster this earnings season. According to an article on ETF trends, without supporting factors, such as price increases or increased mergers and acquisitions to bolster the segment, pharmaceutical exchange traded funds could suffer through a weak start to Q2 2017. Download the free research reports on these stocks today:
Hatfield, the UK-based Mylan N.V.'s shares gained 1.60%, closing Wednesday's trading session at $37.44. The stock recorded a trading volume of 6.16 million shares, which was above its three months average volume of 5.80 million shares. The Company's shares have advanced 2.63% over the previous three months. The stock is trading 7.28% below its 200-day moving average. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have a Relative Strength Index (RSI) of 37.79.
On April 17th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $48 a share to $46 a share.
On April 20th, 2017, Mylan announced the US launch of Perphenazine Tablets USP, a generic version of the reference-listed drug, Trilafon Tablets, originally marketed by Schering. Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. See our free and comprehensive research report on MYL at:
On Wednesday, shares in Dublin, Ireland headquartered Allergan PLC recorded a trading volume of 1.92 million shares. The stock rose 0.54%, ending the day at $239.50. The Company's shares have advanced 0.05% in the past month, 12.46% in the previous three months, and 14.37% on an YTD basis. The stock is trading above its 200-day moving average by 4.94%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 52.17.
On April 25th, 2017, Allergan announced that it has been granted marketing authorization by the US FDA for TrueTear™ Intranasal Tear Neurostimulator, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. AGN free research report PDF is just a click away at:
Dublin, Ireland headquartered Horizon Pharma PLC's stock finished the day 1.25% higher at $15.35 with a total trading volume of 1.75 million shares. The Company's shares have advanced 3.44% in the last one month. The stock is trading below its 50-day moving average by 0.74%. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the US and internationally, have an RSI of 52.69.
On April 13th, 2017, Horizon Pharma announced that its Q1 2017 financial results will be released on Monday, May 08th, 2017. Following the announcement, the management will host a live conference call and webcast at 7:30 a.m. ET to review the Company's financial and operating results. The live webcast and a replay may be accessed on the Company's website. Sign up for your complimentary report on HZNP at:
Shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. ended yesterday's session 2.30% lower at $2.98. The stock recorded a trading volume of 669,448 shares. The Company's shares have advanced 46.80% over the previous three months and 25.21% since the start of this year. The stock is trading 3.92% and 6.37% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 48.54.
On April 25th, 2017, Rigel Pharma announced that it will report its Q1 2017 financial results after market close on Tuesday, May 02nd, 2017. Senior management will follow the announcement with a live conference call and webcast at 5:00 p.m. ET to discuss the financial results. The conference call will be webcast live, and can be accessed on the Company's website. Register for free on Stock-Callers.com and download the latest research report on RIGL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA